ABSTRACT
Non-mass enhancement (NME) is an area of contrast enhancement that does not belong to a three-dimensional mass on magnetic resonance imaging (MRI) and cannot be defined as a focus, and can be evaluated morphologically and kinetically. While NME may belong to benign lesions, it may also be the MRI appearance of an in situ or invasive cancer. Differential diagnosis and management are especially important because the features of benign and malignant lesions overlap and may require MRI-guided biopsy when they cannot be identified by conventional methods. NME is evaluated by its distribution and internal structure properties. Clustered ring internal structure and segmental distribution are the most suspicious findings, and it may be difficult to differentiate with background contrast enhancement. Although it shows the most common type 2 kinetic curve, morphological findings seem to be more valuable in the evaluation. Breast Imaging-Reporting and Data System (BI-RADS) classification recommends the fourth and fifth categories as there is not yet sufficient evidence for the BI-RADS 3 definition. Artificial intelligence also shows promise in this field with its role in digital biopsy.
Keywords:
Non-mass contrast enhancement, breast lesion, MRI
References
1
Lehman CD. Role of MRI in screening women at high risk for breast cancer. J Magn Reson Imaging 2006; 24: 964-70.
2
Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23: 8469-76.
3
D’Orsi CJ, Sickles EA, Mendelson EB, Morris EA, et al. ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology 2013: 56-71.
4
Edwards SD, Lipson JA, Ikeda DM, Lee JM. Updates and revisions to the BI-RADS magnetic resonance imaging lexicon. Magn Reson Imaging Clin N Am 2013; 21: 483-93.
5
Baltzer PA, Benndorf M, Dietzel M, Gajda M, Runnebaum IB, Kaiser WA. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study. AJR Am J Roentgenol 2010; 194: 1658-63.
6
Torous VF, Resteghini NA, Phillips J, Dialani V, Slanetz PJ, Schnitt SJ, et al. Histopathologic correlates of nonmass enhancement detected by breast magnetic resonance imaging. Arch Pathol Lab Med 2021; 145: 1264-9.
7
Shao Z, Wang H, Li X, Liu P, Zhang S, Cao S. Morphological distribution and internal enhancement architecture of contrast-enhanced magnetic resonance imaging in the diagnosis of non-mass-like breast lesions: a meta-analysis. Breast J 2013; 19: 259-68.
8
Tozaki M, Igarashi T, Fukuda K. Breast MRI using the VIBE sequence: clustered ring enhancement in the differential diagnosis of lesions showing non-masslike enhancement. AJR Am J Roentgenol 2006; 187: 313-21.
9
Uematsu T, Kasami M. High-spatial-resolution 3-T breast MRI of nonmasslike enhancement lesions: an analysis of their features as significant predictors of malignancy. AJR Am J Roentgenol 2012; 198: 1223-30.
10
Morakkabati-Spitz N, Leutner C, Schild H, Traeber F, Kuhl C. Diagnostic usefulness of segmental and linear enhancement in dynamic breast MRI. Eur Radiol 2005; 15: 2010-7.
11
Yang QX, Ji X, Feng LL, Zheng L, Zhou XQ, Wu Q, et al. Significant MRI indicators of malignancy for breast non-mass enhancement. J Xray Sci Technol 2017; 25: 1033-44.
12
Yuen S, Uematsu T, Masako K, Uchida Y, Nishimura T. Segmental enhancement on breast MR images: differential diagnosis and diagnostic strategy. Eur Radiol 2008; 18: 2067-75.
13
Ballesio L, Di Pastena F, Gigli S, D’ambrosio I, Aceti A, Pontico M, et al. Non mass-like enhancement categories detected by breast MRI and histological findings. Eur Rev Med Pharmacol Sci 2014; 18: 910-7.
14
Machida Y, Tozaki M, Shimauchi A, Yoshida T. Two distinct types of linear distribution in nonmass enhancement at breast MR imaging: difference in positive predictive value between linear and branching patterns. Radiology 2015; 276: 686-94.
15
Chen ST, Covelli J, Okamoto S, Daniel BL, DeMartini WB, Ikeda DM. Clumped vs non-clumped internal enhancement patterns in linear non-mass enhancement on breast MRI. Br J Radiol 2021; 94: 20201166.
16
Gutierrez RL, DeMartini WB, Eby PR, Kurland BF, Peacock S, Lehman CD. BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement. AJR Am J Roentgenol 2009; 193: 994-1000.
17
Sakamoto N, Tozaki M, Higa K, Tsunoda Y, Ogawa T, Abe S, et al. Categorization of non-mass-like breast lesions detected by MRI. Breast Cancer 2008; 15: 241-6.
18
Mahoney MC, Gatsonis C, Hanna L, DeMartini WB, Lehman C. Positive predictive value of BI-RADS MR imaging. Radiology 2012; 264: 51-8.
19
Gity M, Ghazi Moghadam K, Jalali AH, Shakiba M. Association of different MRI BIRADS descriptors with malignancy in non mass-like breast lesions. Iran Red Crescent Med J 2014; 16: e26040.
20
Asada T, Yamada T, Kanemaki Y, Fujiwara K, Okamoto S, Nakajima Y. Grading system to categorize breast MRI using BI-RADS 5th edition: a statistical study of non-mass enhancement descriptors in terms of probability of malignancy. Jpn J Radiol 2018; 36: 200-8.
21
Aydin H. The MRI characteristics of non-mass enhancement lesions of the breast: associations with malignancy. Br J Radiol 2019; 92: 20180464.
22
Chikarmane SA, Michaels AY, Giess CS. Revisiting nonmass enhancement in breast MRI: analysis of outcomes and follow-up using the updated BI-RADS Atlas. AJR Am J Roentgenol 2017; 209: 1178-84.
23
Shimauchi A, Ota H, Machida Y, Yoshida T, Satani N, Mori N, et al. Morphology evaluation of nonmass enhancement on breast MRI: effect of a three-step interpretation model for readers’ performances and biopsy recommendations. Eur J Radiol 2016; 85: 480-8.
24
Panigrahi B, Harvey SC, Mullen LA, Falomo E, Di Carlo P, Lee B, et al. Characteristics and outcomes of BI-RADS 3 lesions on breast MRI. Clin Breast Cancer 2019; 19: 152-9.
25
Spick C, Bickel H, Polanec SH, Baltzer PA. Breast lesions classified as probably benign (BI-RADS 3) on magnetic resonance imaging: a systematic review and meta-analysis. Eur Radiol 2018; 28: 1919-28.
26
Giess CS, Yeh ED, Raza S, Birdwell RL. Background parenchymal enhancement at breast MR imaging: normal patterns, diagnostic challenges, and potential for false-positive and false-negative interpretation. Radiographics 2014; 34: 234-47.
27
Yang QX, Ji X, Feng LL, Zheng L, Zhou XQ, Wu Q, et al. Significant MRI indicators of malignancy for breast non-mass enhancement. J Xray Sci Technol 2017; 25: 1033-44.
28
Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292: 2735-42.
29
Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Giger M, et al. DCEMRI of breast lesions: is kinetic analysis equally effective for both mass and nonmass-like enhancement? Med Phys 2008; 35: 3102-9.
30
Mori N, Sheth D, Abe H. Nonmass enhancement breast lesions: diagnostic performance of kinetic assessment on ultrafast and standard dynamic contrast-enhanced MRI in comparison with morphologic evaluation. AJR Am J Roentgenol 2020; 215: 511-8.
31
Baltzer PA, Dietzel M, Kaiser WA. Nonmass lesions in magnetic resonance imaging of the breast: additional T2-weighted images improve diagnostic accuracy. J Comput Assist Tomogr 2011; 35: 361-6.
32
Uematsu T. Focal breast edema associated with malignancy on T2-weighted images of breast MRI: peritumoral edema, prepectoral edema, and subcutaneous edema. Breast Cancer 2015; 22: 66-70.
33
Bickelhaupt S, Laun FB, Tesdorff J, Lederer W, Daniel H, Stieber A, et al. Fast and Noninvasive Characterization of Suspicious Lesions Detected at Breast Cancer X-ray screening: capability of diffusion-weighted MR imaging with MIPs. Radiology 2016; 278: 689-97.
34
Avendano D, Marino MA, Leithner D, Thakur S, Bernard-Davila B, Martinez DF, et al. Limited role of DWI with apparent diffusion coefficient mapping in breast lesions presenting as non-mass enhancement on dynamic contrast-enhanced MRI. Breast Cancer Res 2019; 21: 136.
35
Bickel H, Pinker K, Polanec S, Magometschnigg H, Wengert G, Spick C, et al. Diffusion-weighted imaging of breast lesions: Region-of-interest placement and different ADC parameters influence apparent diffusion coefficient values. Eur Radiol 2017; 27: 1883-92.
36
Pinker K, Chin J, Melsaether AN, Morris EA, Moy L. Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment. Radiology 2018; 287: 732-47.
37
Li Y, Yang ZL, Lv WZ, Qin YJ, Tang CL, Yan X, et al. Non-mass enhancements on DCE-MRI: development and validation of a radiomics-based signature for breast cancer diagnoses. Front Oncol 2021; 11: 738330.
38
Tan Y, Mai H, Huang Z, Zhang L, Li C, Wu S, et al. Additive value of texture analysis based on breast MRI for distinguishing between benign and malignant non-mass enhancement in premenopausal women. BMC Med Imaging 2021; 21: 48.